Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
Maryam I AzeemAjay K NookaUma ShanmugasundaramNarayanaiah CheedarlaSayalee PotdarRenee Julia ManaloAlberto C MorenoJeffrey M SwitchenkoSuneethamma CheedarlaDeon Bryant DoxieRoman RadzievskiMadison Leigh EllisKelly E ManningBushra WaliRajesh M ValanparambilKathryn T MaplesEssence BaymonJonathan L KaufmanCraig C HofmeisterNisha S JosephSagar LonialJohn D RobackAlessandro SetteRajesh M ValanparambilMehul S SutharAndrew S NeishMadhav V DhodapkarKavita M DhodapkarPublished in: Blood cancer discovery (2023)
Three doses of SARS-CoV-2 mRNA vaccines fail to yield detectable VOC nAbs in nearly 60% and spike-specific CD8+ T cells in >80% of myeloma patients. Patients who develop breakthrough infections following vaccination have low levels of live-virus nAb. This article is highlighted in the In This Issue feature, p. 101.